Immune checkpoint blockade (ICB) therapy exerts anti-tumor efficacy mainly by activating intratumoral CD8<sup>+</sup> T cells but fails to re-activate terminally exhausted CD8<sup>+</sup> T cells. This evidence concerns the gene CD8A and neoplasm.